Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Director/PDMR Shareholding
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), was notified on the 6 May 2022 that on 26 April 2022 Michael McMahon, Non-Executive Director, purchased 449,333 of shares in Surgical Innovations (the "Ordinary Shares") at a price of 2.22 pence per share.
Following this transaction, Michael McMahon has a combined beneficial holding in the Company of 19,430,962 Ordinary Shares, representing approximately 2.08% of the issued share capital of the Company.
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | ||
David Marsh, CEO | Tel: 0113 230 7597 | ||
Charmaine Day, CFO | | ||
| | | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / Rachel Hayes | | ||
| | | ||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Michael McMahon |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification/ Amendment | Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Surgical Innovations Group plc |
| b) | LEI | 2138004GHGUH3HUZE156 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares of 1p
GB0004016704 | |||
| b) | Nature of the transactions | Transfer of Ordinary Shares | |||
| c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| 2.22 pence per share | 449,333 | ||||
|
| |||||
| d) | Aggregated information - Aggregated volume - Price | 224,575 @ 2.2213p 224,758 @ 2.2195 p | |||
| e) | Date of the transaction | 26 April 2022 | |||
| f) | Place of the transaction | London Stock Exchange, AIM | |||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
